Angelika Amon’s journey from her native Vienna, Austria, to Cambridge, Massachusetts, has been marked by milestones attesting to her ambition. Amon nursed a bottomless curiosity about the natural world at an early age and became smitten with cell biology in high school when a teacher showed the class movies of plant cells parceling out chromosomes during division.

That adolescent infatuation portended Amon’s scientific research into the logic of the cell cycle—the perfectly timed succession of steps through which living cells replicate genetic material, split contents, and divide. Her efforts have revealed that the timely breakdown of proteins called cyclins helps ensure the cycle’s orderly progression.

“This work really showed how one stage of the cell cycle sets up the next,” says Amon.

Amon arrived in the United States in 1994 to the Whitehead Institute for Biomedical Research in Cambridge, where she pursued a postdoctoral stint and earned a prestigious Whitehead fellowship for young scientists. She then struck out on her own, using genetic techniques to unravel the complex web of signals that orchestrate cell division in yeast.

Researching yeast led her to study a condition called aneuploidy—the presence of an abnormal number of chromosomes within a cell, which can lead to illnesses like Down syndrome. Amon is best known for her work on how aneuploidy throws vital cell functions into disarray—work that took shape at MIT’s Koch Institute for Integrative Cancer Research, where she was appointed a faculty member in 1999.

Considered among the world’s leading geneticists and experts on cell division, Amon has broadened her arena into the biggest human scourge brought about by unchecked cell division: cancer. Recently, she and her colleagues found that aneuploid human cells trigger an innate immune response, which helps curb runaway cell division, hinting at a potential new therapeutic approach for the oncological world.

Awards and Accomplishments

• Breakthrough Prize in Life Sciences (2019)
• Vanderbilt Prize in Biomedical Sciences (2018)
• American Academy of Arts and Sciences, Member (2017)
• Elected Foreign Associate to EMBO (2015)
• Elected Foreign Associate to the Austrian Academy of Sciences (2015)
• Genetics Society of America Medal (2014)
• Ernst Jung Prize for Medicine (2013)
• National Academy of Sciences, Member (2010)
• National Academy of Sciences Award in Molecular Biology (2008)
• Paul Marks Prize (2007)
• ASBMB Amgen Award (2007)
• Alan T. Waterman Award (2003)
• Eli Lilly and Company Research Award (2003)
• Howard Hughes Medical Institute, HHMI Investigator (2000)